Meeting
2021 ASCO Annual Meeting
Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.
Authors
Michael B. Atkins
Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
Michael B. Atkins , Cristina Julian , Matthew H. Secrest , Janet Lee , Ana Maria Abajo Guijarro , Edward Francis Mckenna Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9577)
DOI
10.1200/JCO.2021.39.15_suppl.9577
Abstract #
9577
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2015 ASCO Annual Meeting
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.
First Author: Jennifer Ann Wargo
Poster
2022 ASCO Annual Meeting
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence.
First Author: Elisabeth Livingstone